Hemophilia
We recommend
Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?
Podání infuze s koncentrátem aktivovaného protrombinového komplexu (aPCC) při standardizované rychlosti 2 U/kg/min může být zvláště při potřebě opakovaných aplikací časově náročné. Autoři níže citované čerstvě publikované multicentrické studie se proto zaměřili na bezpečnost a tolerabilitu o 50 % sníženého objemu infuze a její rychlosti zvýšené na 4 a 10 U/kg/min.
Results of Prophylactic Treatment of Severe von Willebrand Disease with Recombinant vWF
Níže citovaná studie fáze III hodnotila účinnost a bezpečnost 12měsíční profylaxe rekombinantním…
Evaluation of Joint Condition in Daily Practice in the Era of New Hemophilia Treatment
With the development of new treatment options for hemophilia, there has also been progress in…
Articles on this topic
Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
Japanese authors investigated the mechanism of reduced efficacy of emicizumab in an adult…
Cost-Effectiveness of Preparations Used to Stop Bleeding in Patients with AHA
Choosing the right preparation to manage acute bleeding in patients with acquired hemophilia A…
Risk of Developing Inhibitors in People with Milder Forms of Hemophilia
Moderate and mild hemophilia A differ from the severe form not only in clinical course and…
Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for…
Monitoring of Joint Health is an Important Part of Hemophilia Care
Joint health has become a key aspect of the quality of life for people with hemophilia. The…
What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment...
Sport and Physical Activity Benefit Hemophiliacs
Sport and physical activity are beneficial for individuals with hemophilia. This statement was…
International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with…
COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct…
Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a…
Subscribe
E-courses on this topic
Most read on this topic
- International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
- Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
- Administration of aPCC as a Prevention of Bleeding After Major Cardiac Surgical Procedures
- COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
- What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
- Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
Journal on this topic
Related topic
Interesting links